All Gilead articles
-
PodcastRemdesivir
Will new clinical trials for Covid-19 give remdesivir a second chance? Ben Valsler introduces the broad-spectrum antiviral that didn’t quite make it as the Ebola drug it was originally planned to be
-
BusinessEurope opens gates to CAR-T
First two modified T-Cell cancer therapies approved in the EU, but prices may be prohibitive for public health systems
-
BusinessUS to invest $160m in cancer partnership
Funds will be backed up with $55m from 11 companies to advance new cancer treatments that harness the immune system
-
-
BusinessChina approves BMS’s hepatitis C drugs
Combination is first all-oral treatment in China, where Gilead’s Sovaldi is not yet approved
-
BusinessJudge voids Merck & Co’s $200m patent claim
‘Serious misconduct’ kills case over Gilead’s hepatitis C drugs
-
BusinessGilead loses to Merck & Co in hepatitis C drug dispute
US court upholds Merck’s claim to patents related to blockbuster drugs
-
Business
Merck & Co joins hepatitis C party
New drug adds new treatment options and increases competition in premium market
-
-
BusinessHepatitis C drug patent challenged in Europe
Campaign group says Gilead’s expensive blockbuster sofosbuvir is not innovative enough to warrant a patent
-
-
Business
Gilead licenses generic hepatitis C drug in India
Company aims to head off competition and grab a slice of royalties
-
BusinessNew wave of hepatitis C drugs hits US shore
J&J’s once-daily drug approved by FDA, but rivals are hot on its heels
-
Business
Gilead buys YM for $510m
Deal gives Gilead access to Janus kinase inhibitor CYT387 for the treatment of myelofibrosis